网站地图 加入收藏 中文 English
 
首页 中心概况 组织机构 研究队伍 科学研究 人才培养 交流合作 支撑服务 人才招聘 下载专区 联系我们
当前位置:首页 - 研究队伍
曹彬

姓名:曹彬                            

邮箱:

caobin_ben@163.com

学科方向:

呼吸病学

研究方向:

本实验室长期致力于急性呼吸道感染及新发突发呼吸道传染病关键科学问题的研究,在流感病毒、新型冠状病毒、腺病毒和耐药细菌所致呼吸感染的流行病学、病原学、免疫学机制和临床救治领域取得了具有国际影响的创新性成果,研究结果纳入多个国内外临床治疗指南。主要研究领域包括:

1. 病毒性肺炎的流行病学、临床特点

2. 流感病毒感染的致病机制,病毒性感染中毒症的发生机制

3. 耐药呼吸道病原体感染的诊断、治疗及耐药机制

 

代表性科研论文:8-20篇)

1. J. Yu, H. Li, J. Jia, Z. Huang, S. Liu, Y. Zheng, S. Mu, X. Deng, X. Zou, Y. Wang, X. Shang, D. Cui, L. Huang, X. Feng, W. J. Liu and B. Cao: Pandemic influenza A (H1N1) virus causes abortive infection of primary human T cells. Emerg Microbes Infect, 1-35 (2022)

2. L. Huang, Q. Yao, X. Gu, Q. Wang, L. Ren, Y. Wang, P. Hu, L. Guo, M. Liu, J. Xu, X. Zhang, Y. Qu, Y. Fan, X. Li, C. Li, T. Yu, J. Xia, M. Wei, L. Chen, Y. Li, F. Xiao, D. Liu, J. Wang, X. Wang and B. Cao: 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet, 398(10302), 747-758 (2021)

3. H. Li, L. Liu, D. Zhang, J. Xu, H. Dai, N. Tang, X. Su and B. Cao: SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 395(10235), 1517-1520 (2020)

4. Y. Wang, D. Zhang, G. Du, R. Du, J. Zhao, Y. Jin, S. Fu, L. Gao, Z. Cheng, Q. Lu, Y. Hu, G. Luo, K. Wang, Y. Lu, H. Li, S. Wang, S. Ruan, C. Yang, C. Mei, Y. Wang, D. Ding, F. Wu, X. Tang, X. Ye, Y. Ye, B. Liu, J. Yang, W. Yin, A. Wang, G. Fan, F. Zhou, Z. Liu, X. Gu, J. Xu, L. Shang, Y. Zhang, L. Cao, T. Guo, Y. Wan, H. Qin, Y. Jiang, T. Jaki, F. G. Hayden, P. W. Horby, B. Cao and C. Wang: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 395(10236), 1569-1578 (2020)

5. B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B. Song, Y. Cai, M. Wei, X. Li, J. Xia, N. Chen, J. Xiang, T. Yu, T. Bai, X. Xie, L. Zhang, C. Li, Y. Yuan, H. Chen, H. Li, H. Huang, S. Tu, F. Gong, Y. Liu, Y. Wei, C. Dong, F. Zhou, X. Gu, J. Xu, Z. Liu, Y. Zhang, H. Li, L. Shang, K. Wang, K. Li, X. Zhou, X. Dong, Z. Qu, S. Lu, X. Hu, S. Ruan, S. Luo, J. Wu, L. Peng, F. Cheng, L. Pan, J. Zou, C. Jia, J. Wang, X. Liu, S. Wang, X. Wu, Q. Ge, J. He, H. Zhan, F. Qiu, L. Guo, C. Huang, T. Jaki, F. G. Hayden, P. W. Horby, D. Zhang and C. Wang: A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 382(19), 1787-1799 (2020)

6. F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y. Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen and B. Cao: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229), 1054-1062 (2020)

7. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497-506 (2020)

8. H. Li, X. Gu, H. Li, F. Gong, J. Xu, Y. Wang, H. Li, S. Ruan, Q. Yang and B. Cao: Risk Factors of Viral RNAaemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19. Chest, 159(4), 1382-1386 (2021)

9. J. Xu, Y. Teng, L. Shang, X. Gu, G. Fan, Y. Chen, R. Tian, S. Zhang and B. Cao: The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. Clin Infect Dis, 72(11), e901-e913 (2021)

10. H. Li, X. Cui, L. Sun, X. Deng, S. Liu, X. Zou, B. Li, C. Wang, Y. Wang, Y. Liu, B. Lu and B. Cao: High concentration of Cas12a effector tolerates more mismatches on ssDNA. Faseb j, 35(1), e21153 (2021)

11. S. Duan, X. Gu, G. Fan, F. Zhou, G. Zhu and B. Cao: C-reactive protein or procalcitonin combined with rhinorrhea for discrimination of viral from bacterial infections in hospitalized adults in non-intensive care units with lower respiratory tract infections. BMC Pulm Med, 21(1), 308 (2021)

12. J. Zhao, Y. Zhang, Y. Fan, J. Han, Z. Xiong, X. Liu, B. Li, B. Lu and B. Cao: Characterization of an NDM-5-producing hypervirulent Klebsiella pneumoniae sequence type 65 clone from a lung transplant recipient. Emerg Microbes Infect, 10(1), 396-399 (2021)

13. Z. Liu, Y. Li, X. Tian, Q. Liu, E. Li, X. Gu, M. Liu, J. Xu, Z. He, Y. Huang, S. Xu, G. Lai, Y. Chen, X. Zhang, T. Zhang, J. Xu, L. Zhu, J. Qu and B. Cao: Airway-invasion-associated pulmonary computed tomography presentations characteristic of invasive pulmonary Aspergillosis in non-immunocompromised adults: a National Multicenter Retrospective Survey in China. Respir Res, 21(1), 173 (2020)

14. Y. Wang, W. Zhong, A. Salam, J. Tarning, Q. Zhan, J. A. Huang, H. Weng, C. Bai, Y. Ren, K. Yamada, D. Wang, Q. Guo, Q. Fang, S. Tsutomu, X. Zou, H. Li, A. Gillesen, L. Castle, C. Chen, H. Li, J. Zhen, B. Lu, J. Duan, L. Guo, J. Jiang, R. Cao, G. Fan, J. Li, F. G. Hayden, C. Wang, P. Horby and B. Cao: Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine, 62, 103125 (2020)

15. F. Zhou, Y. Wang, Y. Liu, X. Liu, L. Gu, X. Zhang, Z. Pu, G. Yang, B. Liu, Q. Nie, B. Xue, J. Feng, Q. Guo, J. Liu, H. Fan, J. Chen, Y. Zhang, Z. Xu, M. Pang, Y. Chen, X. Nie, Z. Cai, J. Xu, K. Peng, X. Li, P. Xiang, Z. Zhang, S. Jiang, X. Su, J. Zhang, Y. Li, X. Jin, R. Jiang, J. Dong, Y. Song, H. Zhou, C. Wang and B. Cao: Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J, 54(2) (2019)

16. X. Jia, B. Liu, L. Bao, Q. Lv, F. Li, H. Li, Y. An, X. Zhang, B. Cao and C. Wang: Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog, 14(11), e1007428 (2018)

17. H. Li, K. C. Bradley, J. S. Long, R. Frise, J. W. Ashcroft, L. C. Hartgroves, H. Shelton, S. Makris, C. Johansson, B. Cao and W. S. Barclay: Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. PLoS Pathog, 14(1), e1006821 (2018)

18. B. Cao, G. H. Huang, Z. H. Pu, J. X. Qu, X. M. Yu, Z. Zhu, J. P. Dong, Y. Gao, Y. X. Zhang, X. H. Li, J. H. Liu, H. Wang, Q. Xu, H. Li, W. Xu and C. Wang: Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest, 145(1), 79-86 (2014)

19. C. Wang, B. Cao, Q. Q. Liu, Z. Q. Zou, Z. A. Liang, L. Gu, J. P. Dong, L. R. Liang, X. W. Li, K. Hu, X. S. He, Y. H. Sun, Y. An, T. Yang, Z. X. Cao, Y. M. Guo, X. M. Wen, Y. G. Wang, Y. L. Liu and L. D. Jiang: Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med, 155(4), 217-25 (2011)

20. B. Cao, X. W. Li, Y. Mao, J. Wang, H. Z. Lu, Y. S. Chen, Z. A. Liang, L. Liang, S. J. Zhang, B. Zhang, L. Gu, L. H. Lu, D. Y. Wang and C. Wang: Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med, 361(26), 2507-17 (2009)

 

 

版权所有 999.8vnsr威尼斯人网站有限责任公司 京ICP备15006448号-5